Overview

The marketing authorisation for Opgenra has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (709.65 KB - PDF)

View

español (ES) (582.84 KB - PDF)

View

čeština (CS) (592.56 KB - PDF)

View

dansk (DA) (583.5 KB - PDF)

View

Deutsch (DE) (590.01 KB - PDF)

View

eesti keel (ET) (520.97 KB - PDF)

View

ελληνικά (EL) (661.16 KB - PDF)

View

français (FR) (524.93 KB - PDF)

View

italiano (IT) (525.11 KB - PDF)

View

latviešu valoda (LV) (658.97 KB - PDF)

View

lietuvių kalba (LT) (552.27 KB - PDF)

View

magyar (HU) (583.85 KB - PDF)

View

Malti (MT) (672.79 KB - PDF)

View

Nederlands (NL) (541.61 KB - PDF)

View

polski (PL) (667.42 KB - PDF)

View

português (PT) (537.23 KB - PDF)

View

română (RO) (553.82 KB - PDF)

View

slovenčina (SK) (1.03 MB - PDF)

View

slovenščina (SL) (583.13 KB - PDF)

View

Suomi (FI) (522.19 KB - PDF)

View

svenska (SV) (521.89 KB - PDF)

View

Product information

български (BG) (1.87 MB - PDF)

View

español (ES) (1.2 MB - PDF)

View

čeština (CS) (1.62 MB - PDF)

View

dansk (DA) (1.2 MB - PDF)

View

Deutsch (DE) (1.24 MB - PDF)

View

eesti keel (ET) (1.18 MB - PDF)

View

ελληνικά (EL) (1.92 MB - PDF)

View

français (FR) (1.22 MB - PDF)

View

hrvatski (HR) (1.24 MB - PDF)

View

íslenska (IS) (1.17 MB - PDF)

View

italiano (IT) (1.21 MB - PDF)

View

latviešu valoda (LV) (1.62 MB - PDF)

View

lietuvių kalba (LT) (1.27 MB - PDF)

View

magyar (HU) (1.64 MB - PDF)

View

Malti (MT) (1.65 MB - PDF)

View

Nederlands (NL) (1.24 MB - PDF)

View

norsk (NO) (1.19 MB - PDF)

View

polski (PL) (1.63 MB - PDF)

View

português (PT) (1.19 MB - PDF)

View

română (RO) (1.28 MB - PDF)

View

slovenčina (SK) (2.2 MB - PDF)

View

slovenščina (SL) (1.57 MB - PDF)

View

Suomi (FI) (1.2 MB - PDF)

View

svenska (SV) (1.19 MB - PDF)

View

Latest procedure affecting product information: IG/0473/G

01/07/2016

icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (552.36 KB - PDF)

View

español (ES) (464.84 KB - PDF)

View

čeština (CS) (544.1 KB - PDF)

View

dansk (DA) (467.77 KB - PDF)

View

Deutsch (DE) (464.93 KB - PDF)

View

eesti keel (ET) (464.72 KB - PDF)

View

ελληνικά (EL) (548.15 KB - PDF)

View

français (FR) (464.43 KB - PDF)

View

italiano (IT) (464.27 KB - PDF)

View

latviešu valoda (LV) (543.63 KB - PDF)

View

lietuvių kalba (LT) (529.55 KB - PDF)

View

magyar (HU) (507.79 KB - PDF)

View

Malti (MT) (544.35 KB - PDF)

View

Nederlands (NL) (464.48 KB - PDF)

View

norsk (NO) (622.87 KB - PDF)

View

polski (PL) (547.05 KB - PDF)

View

português (PT) (464.65 KB - PDF)

View

română (RO) (527.4 KB - PDF)

View

slovenčina (SK) (994.79 KB - PDF)

View

slovenščina (SL) (476.21 KB - PDF)

View

Suomi (FI) (464.46 KB - PDF)

View

svenska (SV) (481.49 KB - PDF)

View

български (BG) (818.76 KB - PDF)

View

español (ES) (499.15 KB - PDF)

View

čeština (CS) (782.65 KB - PDF)

View

dansk (DA) (678.87 KB - PDF)

View

Deutsch (DE) (624.42 KB - PDF)

View

eesti keel (ET) (609.17 KB - PDF)

View

ελληνικά (EL) (817.11 KB - PDF)

View

français (FR) (700.32 KB - PDF)

View

italiano (IT) (693.06 KB - PDF)

View

latviešu valoda (LV) (765.09 KB - PDF)

View

lietuvių kalba (LT) (722.78 KB - PDF)

View

magyar (HU) (712.62 KB - PDF)

View

Malti (MT) (761.19 KB - PDF)

View

Nederlands (NL) (627.42 KB - PDF)

View

norsk (NO) (622.87 KB - PDF)

View

polski (PL) (840.43 KB - PDF)

View

português (PT) (699.86 KB - PDF)

View

română (RO) (732.14 KB - PDF)

View

slovenčina (SK) (142.87 KB - PDF)

View

slovenščina (SL) (605.13 KB - PDF)

View

Suomi (FI) (604.16 KB - PDF)

View

svenska (SV) (481.49 KB - PDF)

View

Product details

Name of medicine
Opgenra
Active substance
eptotermin alfa
International non-proprietary name (INN) or common name
eptotermin alfa
Therapeutic area (MeSH)
Spondylolisthesis
Anatomical therapeutic chemical (ATC) code
M05BC02

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

Opgenra is indicated for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.

Authorisation details

EMA product number
EMEA/H/C/000819
Marketing authorisation holder
Olympus Biotech International Limited

Block 2
International Science Centre
National Technology Park
Castletroy
Limerick
Ireland

Marketing authorisation issued
19/02/2009
Revision
9

Assessment history

This page was last updated on

Share this page